Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants

Steven J. Smith, PhD; Gary T. Pauly, PhD; Aamir Akram, MS; Kevin Melody, MS; Zandrea Ambrose, PhD; Joel P. Schneider, PhD; Stephen H. Hughes, PhD

Disclosures

J Acquir Immune Defic Syndr. 2016;72(5):485-491. 

In This Article

Materials and Methods

NNRTI Synthesis

DOR synthesis is described in;[16] RPV synthesis is described in.[18]

Cell-based Assays

Virion production and single-round infectivity assays were used to determine antiviral activity (IC50 values) of the compounds as described[19] and discussed in the Supplemental Digital Content, http://links.lww.com/QAI/A822. Selection of NNRTI mutations in HIV-1 is described in the Supplemental Digital Content, http://links.lww.com/QAI/A822.

Vector Constructs

NNRTI-resistant mutations in HIV-1 RT are described in the Supplemental Digital Content, http://links.lww.com/QAI/A822.

Computer Modeling

All modeling of RPV and DOR in the NNRTI binding pocket is described in the Supplemental Digital Content, http://links.lww.com/QAI/A822.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....